|
Costs and funding
| |
|
Costs in relation to obtained general health benefits (including population health changes, morbidity, quality of life, etc.)
|
Systematic reviews [111-113]; Stakeholders’ documents [46,76,114].
|
|
Costs related to behavior change (e.g., costs of an hour of PA gained per person)
|
Systematic reviews [39,51,95,107,111,112,115]; Stakeholders’ documents [46,76,114]; Position reviews [116].
|
|
Total financial costs of interventions/policies (total budget per participant)
|
Systematic reviews [53,95,101,111,112,115,117]; Stakeholders’ documents [45]; Position reviews [8,48,60,78];
|
|
Outcomes
| |
|
Outcomes measured with valid, reliable, and sensitive tools
|
Systematic reviews: Indicated in all included systematic reviews; Stakeholders’ documents [14,44,62].
|
|
Effects specified as clinically significant (e.g., moving from sedentary to physically active)
|
Systematic reviews [53,57,67,96,113,117]; Stakeholders’ documents [10,14,45]; Position reviews [47,79,116].
|
|
Effects on public health-relevant secondary outcomes (proximal, e.g., weight loss, and distal, e.g., heart disease morbidity)
|
Systematic reviews [55,59,74,81,111]; Stakeholders’ documents [14,45,46,118,119];
|
|
Negative consequences (or risks) evaluated
|
Systematic reviews [59,94,101,111,117,120]; Stakeholders’ documents [14,45,106,119]; Position reviews: [8,77,78].
|
|
Measured outcomes include physiological risk factor indices (e.g., BMI, cholesterol)
|
Systematic reviews [32,68,99,104,121].
|
|
Effects’ evaluation: time and effect size
| |
|
Efficiency established and reported (significant effects established in prior trials)
|
Systematic reviews Indicated in all included systematic reviews; Stakeholders’ documents [44,114,119]; Position reviews [107].
|
|
Sustainable effects (mid-term effects [>6 months] and long term effects [>12 months])
|
Systematic reviews [53,55,59,93-95,99,100,102,104,120,122]; Stakeholders’ documents [10,14,106,118,119]; Position reviews [8,47,86].
|
|
Effect sizes (besides significant effects)
|
Systematic reviews [23,28,31,36,75,92,99,122]; Stakeholders’ documents [44,45,63,63 separate for intervention and policies]; Position reviews [60,88].
|
|
Reach
| |
|
Reach (the strategy is likely to involve a large percentage of the target population; reaching entire target population)
|
Systematic reviews [53,59,94,100,107,112,117,123]; Stakeholders’ documents [10,44,63,83,118,119]; Position reviews [8,26,48,86].
|
|
Inclusiveness: health, age, and gender contexts (individuals with low mobility or comorbidities participate; including people of different age within target group)
|
Systematic reviews [53,59,94,100,107,112,117,123]; Stakeholders’ documents [14,44,45,46,62,63,63 (separate entries for intervention and policies), 106]; Position reviews [47,87].
|
|
Cultural competence and social inclusion of interventions/policies (accounts for cultural/minority issues in: recruitment processes, content, setting; familiarity with health practices in respective social/cultural groups)
|
Systematic reviews [27,29,40,53,59,94,100,101,109,112,117,123]; Stakeholders’ documents [43,44,76,83,119,124]; Position reviews [49,61].
|
|
Participation and generalizability of evaluation
| |
|
Generalizability of effects evaluated (effects observed among participants with different characteristics; effects at population level)
|
Systematic reviews [53,67,68,94]; Stakeholders’ documents [118,119].
|
|
Participation rates reported (across stages of evaluation)
|
Systematic reviews [39,53,96,117,120]; Stakeholders’ documents [14,44,118,119]; Position reviews [8].
|
|
Underlying processes and active components
| |
|
Active components identified
|
Systematic reviews [6,23,29,38,111]; Position reviews [88].
|
|
Ongoing monitoring and measurement of delivery and monitoring of materials
|
Systematic reviews [59,96,120]; Stakeholders’ documents [14,46,63,85].
|
